2024. Tirzepatide: Dual GIP/GLP-1 Receptor Agonists, from Molecular to Clinical Practice for Treating Type-2 Diabetes and Obesity. InaJEMD - Indonesian Journal of Endocrinology Metabolism and Diabetes. 1, 2 (Sep. 2024), 96–110.